A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED. Single‐agent selinexor has limited activity in heavily pretreated patients with metastatic triple‐negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side‐effect profile consistent with previous clinical trials. Future studies of selinex...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Shafique, Michael, Ismail‐Khan, Roohi, Extermann, Martine, Sullivan, Dan, Goodridge, Dawn, Boulware, David, Hogue, Deanna, Soliman, Hatem, Khong, Hung, Han, Hyo S.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Clinical Trial Results
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656474/
https://ncbi.nlm.nih.gov/pubmed/30996012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0231
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items